Target Classification and Molecular Binding Mechanism of Nucleic Acid Aptamer Screening

一、Introduction

Nucleic acid aptamers have small molecular weight. They accept easy chemical modification and carry low immunogenicity. These traits support broad use in molecular diagnosis, targeted delivery and protein‑antagonist drug research. Aptamer performance depends heavily on target categories. Proteins and cells are the two most widely‑used screening materials ^[1].

Screening against purified proteins delivers well‑defined target components. Researchers readily isolate aptamers with high affinity. Whole living cells form complex targets. Plenty of membrane proteins, glycans and lipids sit on cell surfaces. Aptamers from cell‑based screening recognize native conformations on real cell membranes. They fit cell‑targeting research better.

Aptamer‑target recognition does not rely on base‑pairing. Single‑stranded nucleic acids fold into stem‑loop, bulge or G‑quadruplex higher‑order structures. Multiple contact points form between these structures and target surface sites ^[2].

Protein‑target and cell‑target screening differ in incubation conditions and interfering factors. Without proper distinction of target properties, aptamers may show good binding in simplified systems yet poor specificity in real‑world samples.

KMD‑Bioscience runs a mature SELEX screening platform. It performs molecular SELEX for protein samples and Cell‑SELEX for cell samples to get candidate aptamer sequences. NGS sequencing, affinity measurement and cellular binding assays complete downstream evaluation. One‑stop services cover full aptamer development from screening to activity assessment.

二、Main Categories of Screening Targets for Aptamers

1. Protein targets

Proteins belong to the classic target type for aptamer discovery. Most early aptamers were screened against purified proteins. Common examples include cytokines, enzymes, receptor extracellular domains, antigens and viral structural proteins. Purified soluble proteins get immobilized on magnetic beads or solid supports for molecular SELEX workflows ^[3].

Merits of protein‑target screening: target composition stays simple, and experimental conditions are easy to adjust. Aptamers that bind specific protein epitopes can be directly acquired. This simplifies follow‑up mapping of aptamer‑protein binding sites.

Limitations also exist. Purified recombinant proteins may lose native folding or post‑translational modifications. Selected aptamers may fail to recognize homologous proteins under native conditions on cell surfaces. In practical projects, protein‑based SELEX often serves as primary screening. Additional cellular validation follows afterwards.

2.Cell targets

Whole living cells serve as screening substrates in CellSELEX. No prior purification of membrane proteins is required. All biomolecules on cell surfaces collectively act as the target pool ^[4]. Available cell materials include tumor cells, pathogeninfected cells and immune cells. Parallel counterselection with negativecontrol cell lines removes nonspecific aptamer sequences.

Aptamers obtained from cellbased screening recognize membrane proteins or glycoconjugates with native conformations. Such candidates match physiological invivo environments better. They suit development of celltargeting probes and delivery vehicles.

Drawbacks come along. Cell surface carries hundreds of distinct biomolecules. Researchers often cannot identify which exact molecule gets bound by isolated aptamers; extra targetidentification experiments become necessary. Besides, cell viability and cell status directly shape screening outputs. Reproducibility proves harder to maintain compared with proteintarget screening.

三、Molecular Binding Mechanisms of Nucleic Acid Aptamers

1.Aptamerprotein binding mechanism

The core event is the formation of specific 3D folded structures by nucleic acid strands. Multiple non‑covalent interactions mediate recognition toward protein surface epitopes. Major driving forces contain hydrogen bonds, electrostatic attraction, hydrophobic and π‑π stacking effects, plus van der Waals forces. The induced‑fit effect plays a critical role.

Some aptamers stay disordered before target contact. Upon protein binding, conformational rearrangement takes place to build stable complexes.

Electrostatic attraction usually triggers initial contact. Negatively‑charged nucleic acid backbones interact with positively‑charged amino‑acid patches on protein surfaces. Hydrogen bonds and π‑π stacking determine recognition specificity. Multiple contact points form between nucleic acid bases, ribose moieties and amino‑acid side‑chains. Van der Waals forces further stabilize assembled complexes.

Aptamers may bind protein grooves or protruding surface regions. Occupying such sites blocks contacts between proteins and their natural ligands and produces antagonistic bio‑functions.

Buffer ion strength and pH heavily influence aptamer‑protein complexes obtained via protein‑target screening. Shifting these parameters can dissociate formed complexes.

2.Aptamercell binding mechanism

Aptamer‑cell interaction represents the sum of many individual contacts between aptamers and surface molecules such as membrane proteins or glycans. Aptamers do not bind whole cells as an integral entity.

Aptamer molecules first diffuse toward plasma membranes. They locate extracellular epitopes of certain membrane proteins and anchor via the non‑covalent forces mentioned above.

Cellular environments contain abundant interfering substances. Serum proteins and other membrane components compete for aptamer binding sites. Strict counter‑selection steps in Cell‑SELEX filter sequences that stick non‑specifically to ordinary cell lines. Some aptamers get internalized together with their bound membrane targets after attachment.

Many aptamers showing strong affinity against purified proteins lose most binding capacity when exposed to complicated whole‑cell systems.

四、Major Bottlenecks of Two Screening Modes and Combined Screening Strategies

For protein‑target screening, the main challenge lies in preserving native protein conformation. Denatured protein material yields aptamers that only recognize mis‑folded protein variants and have no practical value.

For cell‑target screening, common difficulties include unstable cell conditions, enrichment of non‑specific sequences and unknown molecular targets. 

Combined workflows see frequent real‑world application. Researchers run molecular SELEX on purified proteins first to narrow down candidate library diversity. They then perform Cell‑SELEX plus counter‑selection on living cells. This keeps the controllable advantages of protein‑based screening while ensuring aptamers can recognize native targets on cell membranes.

After screening completes, SPR and flow cytometry assays are required. They separately verify aptamer affinity toward proteins and specific binding toward intact cells.

五、Nucleic Acid Aptamer Screening Services of KMD‑Bioscience

1.Project scheme evaluation

Confirm target types according to research requirements. Choose molecular SELEX or CellSELEX. Design counterselection strategies, define library formats and screening cycles.

2.SELEX screening

For protein targets: carry out multiround enrichment with beadimmobilized target molecules. For cell targets: perform positive screening on desired livecell samples and subtractive counterselection with negativecontrol cells to eliminate nonspecific aptamer sequences.

3.Sequencingbased data analysis

Run NGS highthroughput sequencing for libraries from each screening round. Track sequence enrichment trends and pick promising aptamer candidates.

4.Activity validation

Synthesize candidate aptamer sequences. Measure proteintarget affinity using SPR. Use flow cytometry to verify specific cellularbinding performance.

5.Downstream technical support

Provide aptamer truncation optimization and chemical modification. Deliver complete experimental reports, sequencing datasets and synthesized nucleicacid samples. Support earlystage development of diagnostic probes and targeting molecules.

[1] Domsicova M, Korcekova J, Poturnayova A, Breier A. New Insights into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers. Int J Mol Sci. 2024;25(13):6833. Published 2024 Jun 21. doi:10.3390/ijms25136833

[2] Santarpia G, Carnes E. Therapeutic Applications of Aptamers. Int J Mol Sci. 2024;25(12):6742. Published 2024 Jun 19. doi:10.3390/ijms25126742

[3] Ji, C., Wei, J., Zhang, L., Hou, X., Tan, J., Yuan, Q., & Tan, W. (2023). Aptamer-Protein Interactions: From Regulation to Biomolecular Detection. Chemical reviews.

[4] Lyu Y, Chen G, Shangguan D, et al. Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX. Theranostics. 2016;6(9):1440-1452. Published 2016 Jun 15. doi:10.7150/thno.15666

Q：An aptamer shows solid binding signals against purified protein, yet almost no signal appears in flow‑cytometry cell‑binding tests. What are the major causes？

Answer:

1. The recombinant protein used for screening lacks post‑translational modifications. Its spatial conformation differs from native protein expressed on cell surfaces. The aptamer recognizes denatured or non‑native protein forms and cannot bind physiological cell‑surface targets.

2. Target‑protein abundance stays low on cell membranes. Purified screening systems work under high protein concentrations that support detectable binding. Low‑density cell‑surface targets cannot satisfy effective binding conditions.

3. Other membrane molecules and glycans produce steric hindrance on cell surfaces. They shield target epitopes and block aptamers from accessing binding sites.

4. Environmental differences exist between test systems. Serum proteins in cellular assay media competitively adsorb partial aptamer molecules and lower effective aptamer concentration.

Recommended solution: Add Cell‑SELEX cellular counter‑selection steps. Prioritize aptamer candidates that recognize native‑conformation cell‑surface targets. Perform protein‑level affinity validation afterwards.